Improvement Effect of Metformin on Female and Male Reproduction in Endocrine Pathologies and Its Mechanisms
Metformin (MF), a first-line drug to treat type 2 diabetes mellitus (T2DM), alone and in combination with other drugs, restores the ovarian function in women with polycystic ovary syndrome (PCOS) and improves fetal development, pregnancy outcomes and offspring health in gestational diabetes mellitus (GDM) and T2DM. MF treatment is demonstrated to improve the efficiency of in vitro fertilization and is considered a supplementary drug in assisted reproductive technologies. MF administration shows positive effect on steroidogenesis and spermatogenesis in men with metabolic disorders, thus MF treatment indicates prospective use for improvement of male reproductive functions and fertility. MF lacks teratogenic effects and has positive health effect in newborns. The review is focused on use of MF therapy for restoration of female and male reproductive functions and improvement of pregnancy outcomes in metabolic and endocrine disorders. The mechanisms of MF action are discussed, including normalization of metabolic and hormonal status in PCOS, GDM, T2DM and metabolic syndrome and restoration of functional activity and hormonal regulation of the gonadal axis.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Journal of Evolutionary Biochemistry and Physiology
7 publications, 12.73%
|
|
|
Frontiers in Endocrinology
5 publications, 9.09%
|
|
|
International Journal of Molecular Sciences
3 publications, 5.45%
|
|
|
Molecular Biology Reports
2 publications, 3.64%
|
|
|
Российский физиологический журнал им И М Сеченова
2 publications, 3.64%
|
|
|
Endocrine Reviews
1 publication, 1.82%
|
|
|
Journal of Personalized Medicine
1 publication, 1.82%
|
|
|
Cancers
1 publication, 1.82%
|
|
|
BioMedInformatics
1 publication, 1.82%
|
|
|
Bulletin of Experimental Biology and Medicine
1 publication, 1.82%
|
|
|
Inflammopharmacology
1 publication, 1.82%
|
|
|
Ageing Research Reviews
1 publication, 1.82%
|
|
|
Journal of Biochemical and Molecular Toxicology
1 publication, 1.82%
|
|
|
Irish Journal of Medical Science
1 publication, 1.82%
|
|
|
Molecular and Cellular Endocrinology
1 publication, 1.82%
|
|
|
Cureus
1 publication, 1.82%
|
|
|
Veterinary Research Communications
1 publication, 1.82%
|
|
|
Obesity and Metabolism
1 publication, 1.82%
|
|
|
Advances in Medical Sciences
1 publication, 1.82%
|
|
|
Current Drug Therapy
1 publication, 1.82%
|
|
|
Next Materials
1 publication, 1.82%
|
|
|
Toxicon
1 publication, 1.82%
|
|
|
Diabetes, Obesity and Metabolism
1 publication, 1.82%
|
|
|
Annals of Internal Medicine
1 publication, 1.82%
|
|
|
Discover Sustainability
1 publication, 1.82%
|
|
|
ACS Chemical Neuroscience
1 publication, 1.82%
|
|
|
Food Production Processing and Nutrition
1 publication, 1.82%
|
|
|
Журнал эволюционной биохимии и физиологии
1 publication, 1.82%
|
|
|
European Journal of Pharmacology
1 publication, 1.82%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
2
4
6
8
10
12
|
|
|
Springer Nature
11 publications, 20%
|
|
|
Elsevier
9 publications, 16.36%
|
|
|
Pleiades Publishing
7 publications, 12.73%
|
|
|
MDPI
6 publications, 10.91%
|
|
|
Frontiers Media S.A.
6 publications, 10.91%
|
|
|
Wiley
2 publications, 3.64%
|
|
|
Endocrinology Research Centre
2 publications, 3.64%
|
|
|
The Russian Academy of Sciences
2 publications, 3.64%
|
|
|
SAGE
2 publications, 3.64%
|
|
|
The Endocrine Society
1 publication, 1.82%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.82%
|
|
|
American College of Physicians
1 publication, 1.82%
|
|
|
American Chemical Society (ACS)
1 publication, 1.82%
|
|
|
Akademizdatcenter Nauka
1 publication, 1.82%
|
|
|
Japan Society of Histochemistry and Cytochemistry
1 publication, 1.82%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.82%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
